📣Excited to share with the #nephrology community the latest updates in #C3G and primary #ICMPGN clinical trials at #ERA25. If you are a healthcare professional, do not miss the late breaking session: Innovative Kidney Trials at ⏲️15:00 at the Square #nephrology #kidneydisease

We are excited to be at #ERA25 in sunny Vienna🔅. If you are a healthcare professional join us at booth X3.110 to meet the #Sobi team and learn more about #C3G #IC-MPGN #complement #Rare_Sobi #Sobi_nephrology

📣 Save the date! Our symposium at #ERA25, where we will explore the power of #complement inhibition in #C3G and primary #ICMPGN, join Prof Marina Vivarelli, Prof. Matthew Pickering and Prof. Fadi Fakhouri on 🗓️ June 6, 🕙 10:00-11:00 (CEST) in Hall B

Findings on the Sparsentan study: A New Dawn for IgA Nephropathy.

⬇️ Download the visual abstract: www.theisn.org/wp-co...

📽️ Watch the industry webinar: academy.theisn.org/p...

Supported by @travererare.bsky.social

@kidneydoc101.bsky.social is the President Elect of the @theisn.org ! Honoured to call this exceptional woman and Leader my friend and colleague, and look forward to her vibrant contributions to #Kidneyhealth

Sparsentan for FSGS isn’t dead yet… ir.travere.com/news-release...

Join the @theisn.org ! 🌍
We continue our mission in advancing kidney care! The SoMe team is enjoying the #ISNWCN #MedSky #NephSky

FDA greenlights first clinical trials for genetically modified pig kidney transplants in humans Two companies have received FDA approval to conduct clinical trials transplanting genetically modified pig kidneys into patients with kidney failure

Omg omg omg

www.kidneyfund.org/article/fda-...

The 2024 USRDS report is out (a few weeks ago actually)

usrds-adr.niddk.nih.gov/2024

It’s a treasure trove of data for nephrology nerds, aka all of #NephSky

So, short 🧶 on ESRD incidence/prevalence

Fascinating - didn’t learn this at medical school!

This is so very helpful - thanks for putting it all together

Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study - PMLiVE There are currently no treatments that target the underlying cause of C3G or IC-MPGN

The phase 3 VALIANT trial has been evaluating the drug, pegcetacoplan, in patients with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). pmlive.com/pharma_news/... #kidneyhealth

🫘🧬Complement testing in patients with C3 Glomerulopathy

doi.org/10.1093/ndt/...

@ndt journal